Jean-Philippe Pignol

Erasmus MC, Rotterdam, South Holland, Netherlands

Are you Jean-Philippe Pignol?

Claim your profile

Publications (97)356.84 Total impact

  • Amanda Thu Lee Tran · Jean-Philippe Pignol · Gregory J Czarnota · Raffi Karshafian ·

    10/2015; 2(3). DOI:10.18103/mra.v2i3.390
  • Simmyung Yook · Zhongli Cai · Yijie Lu · Mitchell A Winnik · Jean-Philippe Pignol · Raymond M Reilly ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to construct a novel radiation nanomedicine for treatment of breast cancer (BC) expressing epidermal growth factor receptors (EGFR), particularly triple-negative tumors (TNBC). Gold nanoparticles (AuNP; 30 nm) were modified with polyethyleneglycol (PEG) chains (4 kDa) derivatized with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelators for complexing the β-emitter, 177Lu and with PEG chains (5 kDa) linked to panitumumab for targeting BC cells expressing EGFR. The AuNP were further coated with PEG chains (2 kDa) to stabilize the particles to aggregation. The binding and internalization of EGFR-targeted AuNP (177Lu-T-AuNP) into BC cells was studied and compared to non-targeted 177Lu-NT-AuNP. The cytotoxicity of 177Lu-T-AuNP and 177Lu-NT-AuNP was measured in clonogenic assays using BC cells with widely different EGFR densities: MDA-MB-468 (10e6 receptors/cell), MDA-MB-231 (10e5 receptors/cell) and MCF-7 cells (10e4 receptors/cell). Radiation absorbed doses to the cell nucleus of MDA-MB-468 cells were estimated based on subcellular distribution. Darkfield and fluorescence microscopy as well as radioligand binding assays revealed that 177Lu-T-AuNP were specifically bound by BC cells dependent on their EGFR density whereas the binding and internalization of 177Lu-NT-AuNP was significantly lower. The affinity of binding of 177Lu-T-AuNP to MDA-MB-468 cells was reduced by 2-fold compared to 123I-labeled panitumumab (KD= 1.3 ± 0.2 nM vs. 0.7 ± 0.4 nM, respectively). The cytotoxicity of 177Lu-T-AuNP was dependent on the amount of radioactivity incubated with BC cells, their EGFR density and the radiosensitivity of the cells. The clonogenic survival (CS) of MDA-MB-468 cells overexpressing EGFR was reduced to <0.001% at the highest amount of 177Lu-T-AuNP tested (4.5 MBq; 6 × 1011 AuNP per 2.5 × 10e4-1.2 × 10e5 cells). 177Lu-T-AuNP were less effective for killing MDA-MB-231 cells or MCF-7 cells with moderate or low EGFR density (CS = 33.8 ± 1.6% and 25.8 ± 1.2%, respectively). Since the β-particles emitted by 177Lu have a 2 mm range, 177Lu-NT-AuNP were also cytotoxic to BC cells due to a cross-fire effect but 177Lu-T-AuNP were significantly more potent for killing MDA-MB-468 cells overexpressing EGFR than 177Lu-NT-AuNP at all amounts tested. The cross-fire effect of the β-particles emitted by 177Lu may be valuable for eradicating BC cells in tumors that have low or moderate EGFR expression or cells that are not targeted by 177Lu-T-AuNP as a consequence of heterogeneous intratumoral distribution. The radiation dose to the nucleus of a single MDA-MB-468 cell was 73.2 ± 6.7 Gy, whereas 177Lu-NT-AuNP delivered 5.6 ± 0.6 Gy. We conclude that 177Lu-T-AuNP is a promising novel radiation nanomedicine with potential application for treatment of TNBC, in which EGFR is often overexpressed.
    Molecular Pharmaceutics 09/2015; 12(11). DOI:10.1021/acs.molpharmaceut.5b00425 · 4.38 Impact Factor
  • Jean-Philippe Pignol · Cecile Janus ·

    Acta oncologica (Stockholm, Sweden) 07/2015; 54(9):1-3. DOI:10.3109/0284186X.2015.1067719 · 3.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Permanent breast seed implant is an accelerated partial breast irradiation technique realizing the insertion of 103Pd seeds in the seroma after lumpectomy. We report the 5-year efficacy and tolerance for a cohort, pooling patients from 3 clinical trials. Methods and Materials The trials accrued postmenopausal patients with infiltrating ductal carcinoma or ductal carcinoma in situ 3 cm and clear surgical margins, who were node negative, and had a planning target volume <120 cm;bsupe. The outcomes included overall and disease-free survival and local and contralateral recurrence at 5 years. The true local recurrence rate was compared using 2-tailed paired t tests for estimates calculated using the Tufts University ipsilateral breast tumor recurrence and Memorial Sloan Kettering ductal carcinoma in situ nomograms. Results The cohort included 134 patients, and the observed local recurrence rate at a median follow-up period of 63 months was 1.2% 1.2%, similar to the estimate for whole breast irradiation (P=.23), significantly better than for surgery alone (relative risk 0.27; P<.001), and significantly lower than contralateral recurrence (relative risk 0.33; P<.001). The 5-year overall survival rate was 97.4% 1.9%, and the disease-free survival rate was 96.4% 2.1%. At 2 months, 42% of the patients had erythema, 20% induration, and 16% moist desquamation. The rate of mainly grade 1 telangiectasia was 22.4% at 2 years and 24% at 5 years. The rate of asymptomatic induration was 23% at 2 years and 40% at 5 years. Conclusions The 5-year data suggest that permanent breast seed implantation is a safe accelerated partial breast irradiation option after lumpectomy for early-stage breast cancer with a tolerance profile similar to that of whole breast irradiation.
    International journal of radiation oncology, biology, physics 07/2015; 93(3). DOI:10.1016/j.ijrobp.2015.07.2266 · 4.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is the final report of a prospective phase I study which evaluated the feasibility, toxicities, and biochemical control in prostate cancer patients treated with a hypofractionated boost utilizing a fiducial marker-based daily image guidance strategy and small patient-specific PTV margins. Low- and intermediate-risk prostate cancer patients underwent transperineal ultrasound-guided implantation of three gold fiducial markers and were treated with three-dimensional conformal radiotherapy to 42 Gy (2 Gy/day). During the first nine fractions of treatment, pre- and post-treatment electronic portal imaging was performed to calculate intrafraction prostate motion. Patient-specific PTV margins were derived and a 30 Gy (3 Gy/day) intensity modulated radiotherapy boost was delivered (Total dose = 72 Gy in 31 fractions; EQD2 = 81 Gy, α/β = 1.4). Thirty-three patients completed treatment and were followed for a median of 7.2 years (range, 1.2 - 9.5). Seven patients (21%) developed Radiation Therapy Oncology Group (RTOG) late grade 2 GI toxicity and 1 patient (3%) developed late grade 2 GU toxicity. No patients developed late grade 3 GI or GU toxicity. To date, nine patients developed PSA relapse according to the Phoenix criteria. The actuarial five, seven and nine year biochemical control (BC) rates were 87% (95% confidence interval: 69-95), 77% (95% confidence interval: 56-89) and 66% (95% confidence interval: 42-82). Our study demonstrates that the use of prostate fiducial markers in combination with a daily online image guidance protocol permits reduced, patient-specific PTV margins in a hypofractionated treatment scheme. This treatment planning and delivery strategy was well tolerated in the intermediate time frame. The use of very small PTV margins did not result in excessive failures when compared to other radiation regimens of similar radiobiological intensity.
    Radiation Oncology 04/2015; 10(1):95. DOI:10.1186/s13014-015-0400-1 · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Permanent breast seed implants (PBSIs) have been introduced as an alternative to whole breast irradiation with equivalent rates of tumour control but fewer associated morbidities. However, there is some suggestion that tumour location has an effect on cosmesis in patients having PBSI. Therefore, the aim of the present study was to determine whether tumour location can predict long-term cosmesis.
    Journal of Medical Imaging and Radiation Sciences 03/2015; 46(1):85-89. DOI:10.1016/j.jmir.2014.11.004

  • Journal of Medical Imaging and Radiation Sciences 03/2015; 46(1):S13. DOI:10.1016/j.jmir.2015.01.044
  • Arnjeet Sangha · Mark Ruschin · Jean-Philippe Pignol · Danny Vesprini ·

    Journal of Medical Imaging and Radiation Sciences 03/2015; 46(1):S15. DOI:10.1016/j.jmir.2015.01.048
  • [Show abstract] [Hide abstract]
    ABSTRACT: To prospectively capture acute toxicities and pain associated with postmastectomy radiation therapy (PMRT), to analyze patient and treatment risk factors for severe side effects. Women referred for PMRT were prospectively enrolled and assessed weekly during and after radiation therapy. The endpoint included severe National Cancer Institute Common Terminology Criteria for Adverse Effects grade 3 moist desquamation, other skin symptoms, and pain. Of 257 patients, 73 (28.4%) experienced extensive moist desquamation, 84 (32.7%) Common Terminology Criteria for Adverse Effects skin toxicity grade 3, and 57 (22.2%) a pain impacting on daily life activities. Among symptoms only grade 3 moist desquamation was significantly associated with severe pain (P<.001). On multivariate analysis, smoking, high-energy photons, and skin bolus were significantly associated with severe moist desquamation. Skin toxicity doubled for smokers, with 40% severe pain, 48% grade 3 moist desquamation, and 64% grade 3 skin toxicity. Without skin bolus 4.2% had severe pain, none moist desquamation, and 2.1% grade 3 skin toxicity. When skin bolus was used on alternate days, the frequency increased to 15% for pain, 22% for moist desquamation, and 26% for grade 3 skin toxicity. When bolus was used daily, 32% had pain, 41% moist desquamation, and 47% grade 3 skin toxicity. Symptoms peaked 1 to 2 weeks after the end of PMRT. The present cohort study suggests excessive radiation toxicity after PMRT. Among factors associated with an increase of toxicity are smoking habits and the use of skin bolus. Copyright © 2015 Elsevier Inc. All rights reserved.
    International journal of radiation oncology, biology, physics 01/2015; 91(1). DOI:10.1016/j.ijrobp.2014.09.022 · 4.26 Impact Factor
  • Source
    Nirmala Bhoo-Pathy · Jean-Philippe Pignol · Helena M Verkooijen ·

    The Lancet 11/2014; 384(9957):1846. DOI:10.1016/S0140-6736(14)62239-X · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: After breast conserving surgery, early stage breast cancer patients are currently treated with a wide range of radiation techniques including whole breast irradiation (WBI), accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy, or 3D-conformal radiotherapy (3D-CRT). This study compares the mean heart's doses for a left breast irradiated with different breast techniques. An anthropomorphic Rando phantom was modified with gelatin-based breast of different sizes and tumors located medially or laterally. The breasts were treated with WBI, 3D-CRT, or HDR APBI. The heart's mean doses were measured with Gafchromic films and controlled with optically stimulated luminescent dosimeters. Following the model reported by Darby (1), major cardiac were estimated assuming a linear risk increase with the mean dose to the heart of 7.4% per gray. WBI lead to the highest mean heart dose (2.99 Gy) compared to 3D-CRT APBI (0.51 Gy), multicatheter (1.58 Gy), and balloon HDR (2.17 Gy) for a medially located tumor. This translated into long-term coronary event increases of 22, 3.8, 11.7, and 16% respectively. The sensitivity analysis showed that the tumor location had almost no effect on the mean heart dose for 3D-CRT APBI and a minimal impact for HDR APBI. In case of WBI large breast size and set-up errors lead to sharp increases of the mean heart dose. Its value reached 10.79 Gy for women with large breast and a set-up error of 1.5 cm. Such a high value could increase the risk of having long-term coronary events by 80%. Comparison among different irradiation techniques demonstrates that 3D-CRT APBI appears to be the safest one with less probability of having cardiovascular events in the future. A sensitivity analysis showed that WBI is the most challenging technique for patients with large breasts or when significant set-up errors are anticipated. In those cases, additional heart shielding techniques are required.
    Frontiers in Oncology 10/2014; 4:284. DOI:10.3389/fonc.2014.00284
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: During breast-conserving surgery (BCS), surgeons increasingly perform full-thickness closure (FTC) to prevent seroma formation. This could potentially impair precision of target definition for boost and accelerated partial breast irradiation (APBI). The purpose of this study was to investigate the precision of target volume definition following BCS with FTC among radiation oncologists, using various imaging modalities. Methods: Twenty clinical T1-2N0 patients, scheduled for BCS involving clip placement and FTC, were included in the study. Seven experienced breast radiation oncologists contoured the tumor bed on computed tomography (CT), magnetic resonance imaging (MRI) and fused CT-MRI datasets. A total of 361 observer pairs per image modality were analyzed. A pairwise conformity among the generated contours of the observers and the distance between their centers of mass (dCOM) were calculated. Results: On CT, median conformity was 44 % [interquartile range (IQR) 28-58 %] and median dCOM was 6 mm (IQR 3-9 mm). None of the outcome measures improved when MRI or fused CT-MRI were used. In two patients, superficial closure was performed instead of FTC. In these 14 image sets and 42 observer pairs, median conformity increased to 70 %. Conclusions: Localization of the radiotherapy target after FTC is imprecise, on both CT and MRI. This could potentially lead to a geographical miss in patients at increased risk of local recurrence receiving a radiation boost, or for those receiving APBI. These findings highlight the importance for breast surgeons to clearly demarcate the tumor bed when performing FTC.
    Annals of Surgical Oncology 05/2014; 21(12). DOI:10.1245/s10434-014-3801-8 · 3.93 Impact Factor
  • Merrylee A. McGuffin · Jean-Philippe Pignol · Brian Keller ·

    Brachytherapy 03/2014; 13(2):S17–S18. DOI:10.1016/j.brachy.2014.02.220 · 2.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The authors' aims were to model how various factors influence radiation dose enhancement by gold nanoparticles (AuNPs) and to propose a new modeling approach to the dose enhancement factor (DEF). Methods: The authors used Monte Carlo N-particle (MCNP 5) computer code to simulate photon and electron transport in cells. The authors modeled human breast cancer cells as a single cell, a monolayer, or a cluster of cells. Different numbers of 5, 30, or 50 nm AuNPs were placed in the extracellular space, on the cell surface, in the cytoplasm, or in the nucleus. Photon sources examined in the simulation included nine monoenergetic x-rays (10-100 keV), an x-ray beam (100 kVp), and (125)I and (103)Pd brachytherapy seeds. Both nuclear and cellular dose enhancement factors (NDEFs, CDEFs) were calculated. The ability of these metrics to predict the experimental DEF based on the clonogenic survival of MDA-MB-361 human breast cancer cells exposed to AuNPs and x-rays were compared. Results: NDEFs show a strong dependence on photon energies with peaks at 15, 30/40, and 90 keV. Cell model and subcellular location of AuNPs influence the peak position and value of NDEF. NDEFs decrease in the order of AuNPs in the nucleus, cytoplasm, cell membrane, and extracellular space. NDEFs also decrease in the order of AuNPs in a cell cluster, monolayer, and single cell if the photon energy is larger than 20 keV. NDEFs depend linearly on the number of AuNPs per cell. Similar trends were observed for CDEFs. NDEFs using the monolayer cell model were more predictive than either single cell or cluster cell models of the DEFs experimentally derived from the clonogenic survival of cells cultured as a monolayer. The amount of AuNPs required to double the prescribed dose in terms of mg Au/g tissue decreases as the size of AuNPs increases, especially when AuNPs are in the nucleus and the cytoplasm. For 40 keV x-rays and a cluster of cells, to double the prescribed x-ray dose (NDEF = 2) using 30 nm AuNPs, would require 5.1 ± 0.2, 9 ± 1, 10 ± 1, 10 ± 1 mg Au/g tissue in the nucleus, in the cytoplasm, on the cell surface, or in the extracellular space, respectively. Using 50 nm AuNPs, the required amount decreases to 3.1 ± 0.3, 8 ± 1, 9 ± 1, 9 ± 1 mg Au/g tissue, respectively. Conclusions: NDEF is a new metric that can predict the radiation enhancement of AuNPs for various experimental conditions. Cell model, the subcellular location and size of AuNPs, and the number of AuNPs per cell, as well as the x-ray photon energy all have effects on NDEFs. Larger AuNPs in the nucleus of cluster cells exposed to x-rays of 15 or 40 keV maximize NDEFs.
    Medical Physics 11/2013; 40(11):114101. DOI:10.1118/1.4823787 · 2.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine if older women with early stage breast cancer have sufficient decisional support during their breast cancer journey, a questionnaire-based study was conducted at the Sunnybrook Odette Cancer Centre, in Toronto, Ontario, Canada. Women with stages I and II breast cancer, ≥60 years, were contacted upon completion of their adjuvant treatment. A questionnaire was developed based on focus groups, the literature, and consultation with patients and a multidisciplinary team of experts. The questionnaire was divided into six domains as follows: (1) information support surrounding diagnosis, (2) impact of cancer diagnosis on the patient, (3) quality of interaction with healthcare team, (4) decisional support from the healthcare team, (5) additional information needs surrounding treatment decision, and (6) information support during radiation treatment. Ninety-two of 137 patients approached were included in the analysis. Ninety percent were > 60 years at the time of diagnosis and 65 % had stage I invasive breast cancer. The majority of women received adequate decisional support during their cancer journey. Approximately 90 % of women indicated that they received a high level of support during their cancer diagnosis. We found no significant differences in overall decisional support based on age at diagnosis, education level, ethnicity, or the presence of co-morbidities. However, participants desired additional educational resources such as a worksheet, consultation summary, or workbook to assist in making a treatment decision. The majority of participants felt that they had sufficient support while making a treatment decision for breast cancer.
    Journal of Cancer Education 10/2013; 29(1). DOI:10.1007/s13187-013-0558-x · 1.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American Association of Physicists in Medicine Task Group No. 43 (AAPM TG-43) formalism is the standard for seeds brachytherapy dose calculation. But for breast seed implants, Monte Carlo simulations reveal large errors due to tissue heterogeneity. Since TG-43 includes several factors to account for source geometry, anisotropy and strength, we propose an additional correction factor, called the inhomogeneity correction factor (ICF), accounting for tissue heterogeneity for Pd-103 brachytherapy. This correction factor is calculated as a function of the media linear attenuation coefficient and mass energy absorption coefficient, and it is independent of the source internal structure. Ultimately the dose in heterogeneous media can be calculated as a product of dose in water as calculated by TG-43 protocol times the ICF. To validate the ICF methodology, dose absorbed in spherical phantoms with large tissue heterogeneities was compared using the TG-43 formalism corrected for heterogeneity versus Monte Carlo simulations. The agreement between Monte Carlo simulations and the ICF method remained within 5% in soft tissues up to several centimeters from a Pd-103 source. Compared to Monte Carlo, the ICF methods can easily be integrated into a clinical treatment planning system and it does not require the detailed internal structure of the source or the photon phase-space.
    Physics in Medicine and Biology 08/2013; 58(18):6299-6315. DOI:10.1088/0031-9155/58/18/6299 · 2.76 Impact Factor
  • S Mashouf · E Lechtman · A Ravi · B Keller · J Pignol ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Seed brachytherapy is currently used for adjuvant radiotherapy of early stage prostate and breast cancer patients. In this technique low dose rate (LDR) radioactive seeds are permanently implanted across the treatment volume to deliver a prescribed amount of dose. The current standard for calculation of dose surrounding the brachytherapy seeds is based on American Association of Physicist in Medicine Task Group No. 43 (TG43 formalism) which generates the dose in homogeneous water medium. For low energy sources and especially in breast, the absorbed dose is highly influenced by heterogeneities. Our work focuses on the development of a dose calculation algorithm similar to TG43 applicable in heterogeneous media. Methods: An Inhomogeneity Correction Factor (ICF) is introduced as the ratio of absorbed dose in tissue to that in water medium. ICF is a function of tissue properties and independent of source structure. The absorbed dose in tissue can then be calculated by multiplying the dose as calculated by the TG43 formalism times ICF. We used Monte Carlo simulations in a heterogeneous model of breast to benchmark the improvements achieved in the calculation of dose using the ICF methodology. Results: The dose distributions obtained through applying ICF to TG43 protocol agreed very well with those of Monte Carlo simulations. Over all and across the whole calculation domain, the mean relative error was reduced from 40.8% to 12.7% when ICF correction factor is applied to the TG43 protocol. Conclusion: We have developed a new analytical dose calculation method which enables personalized dose calculations in heterogeneous media. The methodology offers several advantages including the use of standard TG43 formalism, fast calculation time and extraction of the ICF parameters directly from Hounsfield Units. Funding: NSERC
    Medical Physics 06/2013; 40(6):336. DOI:10.1118/1.4814995 · 2.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ultrasound elastography is a new imaging technique that can be used to assess tissue stiffness. The aim of this study was to investigate the potential of ultrasound elastography for monitoring treatment response of locally advanced breast cancer patients undergoing neoadjuvant therapy. Fifteen women receiving neoadjuvant chemotherapy had the affected breast scanned before, 1, 4, and 8 weeks following therapy initiation, and then before surgery. Changes in elastographic parameters related to tissue biomechanical properties were then determined and compared to clinical and pathologic tumor response after mastectomy. Patients who responded to therapy demonstrated a significant decrease (P < .05) in strain ratios and strain differences 4 weeks after treatment initiation compared to non-responding patients. Mean strain ratio and mean strain difference for responders was 81 ± 3% and 1 ± 17% for static regions of interest (ROIs) and 81 ± 3% and 6 ± 18% for dynamic ROIs, respectively. In contrast, these parameters were 102±2%, 110±17%, 101±4%, and 109±30% for non-responding patients, respectively. Strain ratio using static ROIs was found to be the best predictor of treatment response, with 100% sensitivity and 100% specificity obtained 4 weeks after starting treatment. These results suggest that ultrasound elastography can be potentially used as an early predictor of tumor therapy response in breast cancer patients.
    Translational oncology 02/2013; 6(1):17-24. DOI:10.1593/tlo.12412 · 2.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the effect of molecularly targeted gold nanoparticles (AuNPs) on tumor radiosensitization both in vitro and in vivo. Human Epidermal Growth Factor Receptor-2 (HER-2)-targeted AuNPs (Au-T) were synthesized by conjugating trastuzumab (Herceptin) to 30 nm AuNPs. In vitro, the cytotoxicity of Au-T or non-targeted AuNPs (Au-P) was assessed by γ-H2AX immunofluorescence microscopy for DNA damage and clonogenic survival assays. In vivo, athymic mice bearing subcutaneous MDA-MB-361 xenografts were treated with a single dose of 11 Gy of 100 kVp X-rays 24 h after intratumoral injection of Au-T (~0.8 mg of Au) or no X-radiation. Normal tissue toxicity was determined by hematology or biochemistry parameters. The combination of Au-P or Au-T with X-ray exposure increased the formation of γ-H2AX foci by 1.7 (P = 0.054) and 3.3 (P = 0.024) fold in comparison to X-radiation alone, respectively. The clonogenic survival of cells exposed to Au-T and X-rays was significantly lower from that of cells exposed to X-radiation alone, which translated to a dose enhancement factor of 1.6. In contrast, survival of cells exposed to Au-P and X-rays versus X-radiation alone were not significantly different. In vivo, the combination of Au-T and X-radiation resulted in regression of MDA-MB-361 tumors by 46 % as compared to treatment with X-radiation (16.0 % increase in tumor volume). No significant normal tissue toxicity was observed. Radiosensitization of breast cancer to X-radiation with AuNPs was successfully achieved with an optimized therapeutic strategy of molecular targeting of HER-2 and intratumoral administration.
    Breast Cancer Research and Treatment 11/2012; 137(1). DOI:10.1007/s10549-012-2338-4 · 3.94 Impact Factor
  • Ivo A Olivotto · Jean-Philippe Pignol ·

    Oncology (Williston Park, N.Y.) 09/2012; 26(9):831, 837. · 2.32 Impact Factor

Publication Stats

2k Citations
356.84 Total Impact Points


  • 2015
    • Erasmus MC
      Rotterdam, South Holland, Netherlands
    • Erasmus Universiteit Rotterdam
      Rotterdam, South Holland, Netherlands
  • 2003-2015
    • University of Toronto
      • • Department of Medical Biophysics
      • • Department of Radiation Oncology
      • • Sunnybrook Health Sciences Centre
      Toronto, Ontario, Canada
  • 2005-2014
    • Sunnybrook Health Sciences Centre
      • Department of Radiation Oncology
      Toronto, Ontario, Canada
  • 2010
    • McMaster University
      Hamilton, Ontario, Canada
  • 2006
    • The Princess Margaret Hospital
      Toronto, Ontario, Canada